- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03346291
Examining Persistence in Smokers With Schizophrenia
15 januari 2019 uppdaterad av: Marc L. Steinberg, Ph.D., Rutgers, The State University of New Jersey
All participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks).
They will complete assessment measures commonly used in smoking cessation studies.
We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is a non-randomized trial of a new psychosocial treatment for smoking cessation (for smokers with schizophrenia) that is based on cognitive behavioral therapy for smoking cessation - a commonly used approach.
Participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks).
They will complete assessment measures commonly used in smoking cessation studies.
We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.
Studietyp
Interventionell
Inskrivning (Faktisk)
27
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rutgers Robert Wood Johnson Medical School
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 64 år (Vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Must be between 18 - 64 years old
- Must indicate commitment to quitting smoking in the next 30 days
- Must smoke at least 5 cigarettes per day for past 6-months
- Expired breath carbon monoxide (CO) > 5 to ensure daily cigarette use
- Must score < 8 (or <7 for women) on the Alcohol Use Disorders Identification Test
- Must score less than 3 on the 6-month Drug Abuse Screening Test-10
- Must provide a negative urine drug screen for cannabis, cocaine, opiates, or
- methamphetamine (Note: Participants with a positive screen for opiates may
- participate with proof of prescription for opiates.)
- Must have a diagnosis of Schizophrenia or Schizoaffective Disorder on Structured Clinical Interview
- Psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen including a stable antipsychotic dose for 8 weeks
Exclusion Criteria:
- Must not be currently receiving tobacco dependence treatment counseling
- Must not currently be taking varenicline (Chantix)
- Must not be taking bupropion (Zyban/Wellbutrin) to quit smoking
- Must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days.
- Must not report unstable angina pectoris, myocardial infarction, or significant cardiac arrhythmia (including atrial fibrillation) in the past 90 days
- Must not be pregnant, breastfeeding, or planning on becoming pregnant in the next 4-months. Women who can become pregnant may be included if using effective birth control
- Must not have pending legal matters with potential to result in jail time
- Must not be planning on moving outside local area in next 3-months
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Persistence Targeted Smoking Cessation
8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
|
individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Task Persistence - Mirror Tracing
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
Number of seconds persisting on a computerized mirror tracing task (Higher number of seconds = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Sustained Divided Attention Task
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
Seconds persisting on Sustained Divided Attention Task (Higher number of seconds = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Breath-holding
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
Number of seconds persisting on a breath-holding endurance task (Higher number of seconds = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence -Temperament and Character Inventory-Persistence Scale (TCI-P)
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on Temperament and Character Inventory-Persistence Scale (TCI-P) (Higher score = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - 2-item Task Persistence Measure
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on 2-item Task Persistence Measure (Higher score = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Distress Tolerance Scale (DTS)
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on Distress Tolerance Scale (DTS) (Higher score = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Thoughts About Smoking Questionnaire
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on the Thoughts About Smoking Questionnaire (Higher score = less persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Self-reported ratings of ease of understanding and helpfulness of counseling
Tidsram: Through end-of-treatment - approximately 8 weeks after baseline
|
percentage of participants who rate the intervention as "easy to understand" and "helpful"
|
Through end-of-treatment - approximately 8 weeks after baseline
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Utredare
- Huvudutredare: Marc L Steinberg, Ph.D., Rutgers, The State University of New Jersey
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 januari 2017
Primärt slutförande (Faktisk)
13 juni 2018
Avslutad studie (Faktisk)
13 juni 2018
Studieregistreringsdatum
Först inskickad
3 november 2017
Först inskickad som uppfyllde QC-kriterierna
14 november 2017
Första postat (Faktisk)
17 november 2017
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
17 januari 2019
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
15 januari 2019
Senast verifierad
1 januari 2019
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 20150001885
- R21DA041163-01 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Nej
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .